Alto Neuroscience (ANRO) Total Debt (2023 - 2026)
Alto Neuroscience (ANRO) reported Total Debt of $16.0 million for Q1 2026, down 19.65% on a YoY basis from $19.9 million in Q1 2025, and down 4.39% sequentially from $16.8 million in Q4 2025.
Alto Neuroscience (ANRO) Total Debt (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Total Debt data on file, last reported at $16.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Debt fell 19.65% year-over-year to $16.0 million; the trailing twelve-month figure through Mar 2026 stood at $16.0 million (down 19.65% YoY), and the FY2025 full-year result was $16.8 million, up 63.42% from the prior year.
- Total Debt declined to $16.0 million in Q1 2026, from $16.8 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $20.3 million in Q3 2025 to a low of $9.9 million in Q4 2023.
- A 4-year average of $15.0 million and a median of $14.9 million in 2024 frame the typical range for Total Debt.
- Across the five-year window, Total Debt soared 79.54% in 2025 and dropped 19.65% in 2026, its largest moves.
- Tracing ANRO's Total Debt over 4 years: stood at $9.9 million in 2023, then advanced by 3.99% to $10.3 million in 2024, then soared by 63.42% to $16.8 million in 2025, then declined by 4.39% to $16.0 million in 2026.
- Business Quant data shows ANRO's Total Debt at $16.0 million in Q1 2026, $16.8 million in Q4 2025, and $20.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.96 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 959.06 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alto Neuroscience | 881.86 Mn | 881.86 Mn | - | 16.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.02 Mn |
| Dec 31, 2025 | 16.76 Mn |
| Sep 30, 2025 | 20.31 Mn |
| Jun 30, 2025 | 20.12 Mn |
| Mar 31, 2025 | 19.94 Mn |
| Dec 31, 2024 | 10.25 Mn |
| Sep 30, 2024 | 13.69 Mn |
| Jun 30, 2024 | 12.38 Mn |
| Mar 31, 2024 | 11.11 Mn |
| Dec 31, 2023 | 9.86 Mn |